What Allos Therapeutics does

Allos Therapeutics operates a causal AI platform designed to improve pharmaceutical development by simulating how interventions affect outcomes before physical experiments are run. The platform functions as a closed-loop learning system that ingests structured data from every experimental run and deviation, providing pharmaceutical developers with a single source of truth featuring traceable drivers, documented assumptions, and controlled version history. The system is organized into four integrated modules spanning the molecule-to-process continuum: Formulation Development (phase-space mapping and simulation-led Design of Experiments), Scale-Up (validated operating windows with early risk signals), Tech Transfer and QA (inspection-aware, version-controlled decisions), and Clinical Trials (real-world data integration and patient stratification).

The company monetizes through enterprise SaaS subscriptions sold via a consultative direct sales motion targeting pharmaceutical companies, with quote-based pricing and 'Talk to a Process Expert' CTAs indicating a solution-selling approach requiring technical validation and regulatory compliance alignment. Reported customer outcomes include 50% lower inter-patient variability and 70% fewer scale-up and technology transfer failures, though these are company-reported without disclosed methodology. The platform emphasizes regulatory compliance and version-controlled decisions to support tech transfer and quality assurance in regulated pharma environments, and headcount is reported at 101-250 employees.

Firmographic inputs (biopharma, anti-cancer therapeutics, founded 1992, Berkeley HQ) and a 2002 funding round from Aisling Capital with Stephen J. Hoffman as Chairman appear to reference the legacy Allos Therapeutics biopharmaceutical company (later acquired by Spectrum Pharmaceuticals) rather than the current AI platform business operating at allos.ai. The current website is treated as the authoritative first-party source for the company's product, technology, and business model.

Name

Allos Therapeutics

Website

https://allos.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

101–250 employees

Short description

Allos Therapeutics operates a causal AI platform for pharmaceutical development, simulating how interventions affect outcomes before physical experiments and learning from every run. Its closed-loop platform serves enterprise pharma developers across formulation, scale-up, tech transfer, QA, and clinical trials.

Ownership category

akta.pro rank

Product category

AI-Driven Pharmaceutical Process Development Software

NAICS

Computer Systems Design and Related Services (54151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industry

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• Causal AI platform
• Pharmaceutical process development
• Formulation development software
• Design of experiments
• Scale-up tech transfer

Headquarters

HQ city

Berkeley

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. AI Platform Subscription: SaaS-based AI platform providing simulation and experimental design capabilities for pharmaceutical development. The platform appears to be sold as an enterprise software solution with licensing and subscription components, likely with professional services for implementation and validation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Allos Therapeutics sells a causal AI software platform that simulates how pharmaceutical interventions affect outcomes before physical experiments are run. The platform combines simulation-led Design of Experiments, phase-space mapping, validated operating windows, inspection-aware decision documentation, and patient stratification into a single closed-loop system covering formulation development, scale-up, tech transfer & QA, and clinical trials for pharmaceutical companies.

Product overview

Allos Therapeutics offers a single unified platform called 'The Allos Platform' — a causal AI solution for pharmaceutical development. The platform integrates four core modules: Formulation Development (phase-space mapping + simulation-led DoE), Scale-Up (validated operating windows + early risk signals), Tech Transfer & QA (inspection-aware, version-controlled decisions), and Clinical Trials (real world data, patient stratification). The platform is designed to work as one closed-loop system from molecule to validated process, with traceable drivers, documented assumptions, and controlled version history serving as the single source of truth.

Differentiator

Problem solved

Functional benefit

Products and services

• The Allos Platform The Allos Platform is a causal AI software system for pharmaceutical development that simulates how interventions affect outcomes before physical experiments are run. It integrates Formulation Development (phase-space mapping and simulation-led DoE), Scale-Up (validated operating windows and early risk signals), Tech Transfer & QA (inspection-aware, version-controlled decisions), and Clinical Trials (real-world data integration and patient stratification) into a single closed-loop system with traceable drivers, documented assumptions, and controlled version history serving as a single source of truth. It is targeted at enterprise pharmaceutical and biotech companies seeking to reduce experiments, lower inter-patient variability, and minimize scale-up and tech-transfer failures.

Quantifiable outcome

• 50% lower inter-patient variability
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Schrödinger: Schrödinger provides computational chemistry and physics-based simulation software for pharma R&D, including formulation and process development. Most directly comparable to Allos in applying simulation-led methods to drug development workflows, with overlapping customer base in pharmaceutical companies.
• Aitia (formerly GNS Healthcare): Aitia applies causal AI specifically to pharmaceutical and biotech R&D, modeling causal relationships in biological systems to accelerate drug discovery and clinical development. Most architecturally comparable to Allos given the shared causal AI methodology and pharma R&D focus.
• Insilico Medicine: Insilico Medicine applies AI/ML across the drug discovery pipeline, from target identification through clinical development. Comparable to Allos as an AI platform serving pharma development workflows, though focused more upstream on discovery than formulation/scale-up.
• Recursion Pharmaceuticals: Recursion uses AI-driven high-throughput experimentation to drive pharmaceutical R&D. Comparable to Allos in combining experimental data with AI for pharma development, though Recursion operates its own internal pipeline rather than primarily as a SaaS platform.
• CytoReason: CytoReason applies AI-driven models of the immune system and disease biology to support pharma R&D and clinical development decisions. Comparable to Allos in serving pharma customers with AI-augmented development insights, including patient stratification and trial design.
• InSilicoTrials: InSilicoTrials provides simulation and digital-twin platforms for clinical trial design and pharmaceutical R&D. Comparable to Allos in applying simulation-led methodology to pharmaceutical development, including regulatory-grade validation pathways.
• XtalPi: XtalPi combines AI, quantum physics, and robotics for drug discovery and formulation development. Comparable to Allos in using AI/simulation to optimize pharmaceutical development, particularly around formulation and crystallization workflows.

Emerging players

• Iambic Therapeutics: Iambic Therapeutics applies AI to drug discovery and design, including physics-informed models. Comparable to Allos as a next-generation AI platform targeting pharmaceutical development, though more discovery-focused than process/formulation-focused.
• Unlearn.AI: Unlearn applies AI to clinical trial design and patient stratification through prognostic digital twins. Comparable to Allos's clinical trial module in applying AI to optimize trial outcomes and patient selection in pharma development.

Broad incumbents

• Dassault Systèmes (BIOVIA): Dassault Systèmes' BIOVIA portfolio provides enterprise scientific software for pharmaceutical R&D, including formulation, scale-up, and quality management. Comparable to Allos as a broader pharma development platform with deeper enterprise install base and regulatory validation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/allos-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allos Therapeutics